NR3C2 and hydrops fetalis: Neurohumoral antagonists including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin-receptor blockers (ARBs), beta-blockers and mineralocorticoid receptor antagonists (MRAs) represent the cornerstones of modern HF therapy and have decreased the mortality and re-hospitalization rates of HF patients.